FdaApplication
BLA 125147
Identifiers
- fda_app_no: BLA125147
Properties
| Property | Value |
|---|---|
| applicant_name | Amgen Inc. |
| application_type | BLA |
| approval_date | 2006-09-27 |
Revenue by product
VECTIBIX
| Period | Revenue |
|---|---|
| Q2 2026 | $338.0M |
| Q1 2026 | $287.0M |
| Q4 2025 | $319.0M |
| Q3 2025 | $284.0M |
| Q2 2025 | $305.0M |
| Q1 2025 | $267.0M |
| Q4 2024 | $246.0M |
| Q3 2024 | $282.0M |
| Q2 2024 | $270.0M |
| Q1 2024 | $247.0M |
| Q4 2023 | $251.0M |
| Q3 2023 | $252.0M |
| Q2 2023 | $248.0M |
| Q1 2023 | $233.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VECTIBIX | PANITUMUMAB | 100MG/5ML (20MG/ML) | INJECTABLE;IV (INFUSION) |
| VECTIBIX | PANITUMUMAB | 200MG/10ML (20MG/ML) | INJECTABLE;IV (INFUSION) |
| VECTIBIX | PANITUMUMAB | 400MG/20ML (20MG/ML) | INJECTABLE;IV (INFUSION) |
3 products